By Dr N Manzini — Cardiothoracic Surgeon
When a child develops a mass in the chest, it can feel as if the world suddenly stops for a family. Parents are thrust into a whirlwind of complex medical jargon, scans, and difficult conversations about cancer and surgery. Childhood thoracic tumours, though rare, represent a significant area in paediatric medicine where early recognition and specialised care can dramatically alter a child’s future.
What Are Childhood Thoracic Tumours?
The thorax contains some of the body’s most vital organs: the heart, lungs, oesophagus, and major blood vessels. Tumours in this region can be either benign (non-cancerous) or malignant (cancerous).
Benign tumours are often curable with surgery alone. These include bronchogenic cysts (fluid-filled growths arising during lung development), hamartomas (disorganised clusters of normal tissue), and inflammatory myofibroblastic tumours, which may still behave aggressively despite being non-cancerous.
Malignant tumours are more complex. Neuroblastoma, arising from nerve tissue near the spine, is most common in infants and toddlers. Lymphomas frequently affect adolescents. Germ cell tumours may appear in the chest. Sarcomas such as Ewing sarcoma or rhabdomyosarcoma may originate in the chest wall, bones, or surrounding connective tissue.
Who Is at Risk?
Most children with thoracic tumours have no family history or obvious risk factor, but patterns exist. Neuroblastomas are more likely in very young children; lymphomas and germ cell tumours appear more often in teenagers. Certain genetic syndromes — Li-Fraumeni or Beckwith–Wiedemann — increase the likelihood of tumour development. Children who have previously received chest radiation may develop new tumours years later.
Clinical Presentation
Presentation varies depending on tumour size and location. Some children present with breathing problems — wheezing, persistent cough, or recurrent chest infections. Others present with compression symptoms: difficulty swallowing, hoarseness, or swelling of the face and arms if a tumour presses on major veins. Systemic symptoms including fever, night sweats, fatigue, and weight loss are common with lymphomas. Occasionally a tumour is discovered incidentally on imaging performed for another reason.
Diagnosis
Evaluation begins with a thorough history and clinical examination looking for signs of localised or systemic spread. A chest X-ray is often the first clue. CT scans provide a detailed three-dimensional view. MRI is especially useful for tumours near the spine or soft tissues. PET scans may help reveal the extent of disease in suspected malignancies.
Tumour markers serve as valuable “fingerprints” in diagnosis:
- Alpha-fetoprotein (AFP) — elevated in germ cell tumours and liver tumours
- Beta-hCG — raised in certain germ cell tumours
- Lactate dehydrogenase (LDH) — often elevated in aggressive tumours such as lymphomas
Biopsy remains the gold standard. Options range from minimally invasive (fine needle aspiration, core biopsy under ultrasound or CT guidance) to open biopsy under general anaesthesia via thoracotomy or VATS.
Treatment Approaches
Treatment is tailored to tumour type. Chemotherapy remains central, with advances including ALK inhibitors for specific mutations, anti-GD2 immunotherapy for neuroblastoma, and CAR-T cell therapy for relapsed lymphomas. Radiotherapy is used more cautiously in children due to long-term side effect risks.
Surgery plays a central role. For benign tumours, surgery is often curative. For malignant tumours, chemotherapy may be used first to shrink the tumour before resection. Complex chest wall resections in sarcomas may require prosthetic reconstruction.
The Role of the Cardiothoracic Surgeon
All patients with suspected chest tumours are discussed at a multidisciplinary team (MDT) meeting — including physicians, oncologists, and thoracic surgeons. Cardiothoracic surgeons are responsible for performing biopsies, removing tumours, and reconstructing the chest when necessary. Their role often extends into survivorship care, managing long-term complications such as chest wall deformities or lung scarring.
Outcomes
The outlook for children with thoracic tumours has improved significantly:
- Benign tumours: Almost always curable with surgery
- Lymphomas: Cure rates above 80–90% with systemic therapy
- Germ cell tumours: Survival rates over 90% with combined therapy
- Neuroblastoma: ~75% survival in low-risk cases; 40–50% in high-risk disease
- Ewing sarcoma: Five-year survival rates of 60–70%
Advances in imaging, chemotherapy, immunotherapy, and surgical techniques have turned what was once a devastating diagnosis into a landscape of real possibility.
🔒 CPD Assessment: This article is linked to a CPD-accredited assessment. Subscribe to the Clinician Edition to earn your CPD points.